New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

“What is important is to create an overview and understanding from different perspectives”

Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...

Claims of life science companies fleeing abroad is a myth according to survey

The claim that life science companies are moving abroad is exaggerated. In fact, only a tiny percentage is leaving the country, according to a survey.

Studie: Därför kan män vara sämre på att bekämpa virusinfektioner

Forskning har visat att hur allvarligt vår kropp reagerar på en virusinfektion kan bero på vårt kön. Men varför könen bekämpar virusinfektioner olika bra har ti...

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

ZEISS Quality Innovation Days

The leading digital event from April 15-19, 2024.

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

Your solution for right part positioning

ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.

Cost-efficient development of laboratory devices

8 ways to optimise development costs and speed up processes

Tidig tilläggsbehandling kan rädda liv på hjärtpatienter enligt studie

Tidig behandling med blodfettsänkande läkemedel ger en bättre prognos för patienter med hjärtinfarkt jämfört med en sent insatt behandling eller ingen behandlin...

Life Science Sweden heads to the Oresund region! ‒ Hello there Michael Linnell

Life Science Sweden’s The Future of Swedish Danish Life Science and New Updates in Drug Formulation & Bioavailability meetings are coming up soon. We asked Mich...

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

The first vaccine derived from cowpox

The British rural doctor could not forget the words of the peasant girl. Could that really be true? A couple of decades later, on 14 May 1796, he performed the ...

Klaria i spanskt samarbete om munfilm från alger

Uppsalabaserade Klaria Pharma har tecknat avtal med det spanska läkemedelsbolaget Pharmamar om utveckling av en alginatfilmsformulering till en av Pharmamars su...

Stor kongress om framtidsutsikter igång i Lund

Vad sker i framtiden inom svensk och dansk life science? Det diskuteras i dag vid eventet The Future of Swedish and Danish Life Science i Lund.

The most important Swedish medical innovations: Our ranking

Life Science Sweden turns 20 years old – and celebrates by producing a top list of the 20 most important contemporary Swedish innovations in the field of medicine.

Novo Nordisk to invest billions in new quality control lab

Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.

”We need compatibility“

Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on ef...

Kriget i Ukraina ger bränsle åt totalt resistenta bakterier

Krigshärjade Ukraina lider inte bara av fientliga attacker från en utländsk angripare, utan också från hotet från en totalt resistent och smittsam bakterie.

Nanexa develops depot formulation of the diabetes and obesity drug Saxenda

Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

Column: "Are we already living in the new normal?"

2020 felt like the year that we were building the house around us whilst moving into it at the same time.